Randomized Controlled Trial of Danoprevir Plus Peginterferon Alfa-2a and Ribavirin in Treatment-Naïve Patients With Hepatitis C Virus Genotype 1 Infection
1 Hôpital Beaujon, Clichy, France;2 The Ottawa Hospital, Division of Infectious Diseases, Ottawa, Ontario, Canada;3 Tulane University Health Sciences Center, New Orleans, Louisiana;4 Montpellier School of Medicine, Montpellier, France;5 University of Utah, Health Sciences Center, Salt Lake City, Utah;6 University of British Columbia, Vancouver, British Columbia, Canada;7 Alamo Medical Research, San Antonio, Texas;8 IFI, Asklepiosklinik St Georg, Hamburg, Germany;9 Medical University of Vienna, Vienna, Austria;10 Nepean Hospital, Penrith, New South Wales, Australia;11 Hoffmann-La Roche Inc, Nutley, New Jersey;12 Roche Products Ltd, Welwyn, United Kingdom;13 Genentech, South San Francisco, California;14 University of California San Francisco, San Francisco, California
